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Abstract
Objectives To examine the safety and effectiveness of cobalt-chromium
everolimus eluting stents compared with bare metal stents.
Design Individual patient data meta-analysis of randomised controlled
trials. Cox proportional regression models stratified by trial, containing
random effects, were used to assess the impact of stent type on
outcomes. Hazard ratios with 95% confidence interval for outcomes
were reported.
Data sources and study selection Medline, Embase, the Cochrane
Central Register of Controlled Trials. Randomised controlled trials that
compared cobalt-chromium everolimus eluting stents with bare metal
stents were selected. The principal investigators whose trials met the
inclusion criteria provided data for individual patients.
Primary outcomes The primary outcome was cardiac mortality.
Secondary endpoints were myocardial infarction, definite stent
thrombosis, definite or probable stent thrombosis, target vessel
revascularisation, and all cause death.
Results The search yielded five randomised controlled trials, comprising
4896 participants. Compared with patients receiving bare metal stents,
participants receiving cobalt-chromium everolimus eluting stents had a
significant reduction of cardiac mortality (hazard ratio 0.67, 95%
confidence interval 0.49 to 0.91; P=0.01), myocardial infarction (0.71,
0.55 to 0.92; P=0.01), definite stent thrombosis (0.41, 0.22 to 0.76;
P=0.005), definite or probable stent thrombosis (0.48, 0.31 to 0.73;
P<0.001), and target vessel revascularisation (0.29, 0.20 to 0.41;
P<0.001) at a median follow-up of 720 days. There was no significant
difference in all cause death between groups (0.83, 0.65 to 1.06; P=0.14).
Findings remained unchanged at multivariable regression after
adjustment for the acuity of clinical syndrome (for instance, acute
coronary syndrome v stable coronary artery disease), diabetes mellitus,
female sex, use of glycoprotein IIb/IIIa inhibitors, and up to one year v
longer duration treatment with dual antiplatelets.
Conclusions This meta-analysis offers evidence that compared with
bare metal stents the use of cobalt-chromium everolimus eluting stents
improves global cardiovascular outcomes including cardiac survival,
myocardial infarction, and overall stent thrombosis.
Introduction
Randomised controlled trials,1 2 a meta-analysis,3 and an
observational study4 have consistently shown reduced rates of
target vessel revascularisation because of angiographic restenosis
and ischaemia after treatment with drug eluting stents compared
with bare metal stents. As a result, most percutaneous coronary
interventions are done with drug eluting stents rather than bare
metal stents. The higher rates of late stent thrombosis and the
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concern about higher risks of late stent thrombosis after early
discontinuation of dual antiplatelet therapy with first generation
drug eluting stents, however, have raised safety concerns.5 6
New drug eluting stents have been developed with novel
materials, designs, and delivery systems, with biocompatible
polymers and new antiproliferative agents. The box gives details
of the types of stents. Most of these second generation stents,
however, were approved after non-inferiority trials in which
they were compared with first generation drug eluting stents.7-10
Few studies have directly compared second generation drug
eluting stents with bare metal stents, and their comparative
safety profile remains unclear.
Recent studies have reported a possible lower risk of stent
thrombosis after implantation with cobalt-chromium everolimus
eluting stents compared with bare metal stents.11-13 The
implications of this finding on clinical outcomes are currently
unknown.
We undertook a collaborative analysis of data from randomised
trials of patients who underwent random allocation to either
cobalt-chromium everolimus eluting stents or bare metal stents
to assess the comparative safety and efficacy of these two
devices on fatal and non-fatal cardiovascular outcomes.
Methods
Search strategy and study selection
Two investigators (MV and GF) independently searched
Medline, Embase, and the Cochrane Central Register of
Controlled Trials (from database inception to December 2013)
using the terms everolimus eluting stent and bare metal stent.
A sensitive filter for randomised controlled trials was used.
There were no restrictions by language, publication date, or
publication status. We hand searched conference proceedings
(from 2006 to 2013) of the American Heart Association, the
American College of Cardiology, the Transcatheter
Cardiovascular Therapeutics, and the European Society of
Cardiology. All suitable non-published completed registered
studies were considered for inclusion. We checked reference
lists of identified articles, recent editorials, and related reviews
and contacted experts for further eligible trials.
Trial eligibility and quality assessment
Two investigators (MV and GF) independently assessed trial
eligibility. Randomised trials comparing two or more different
drug eluting stents or drug eluting stents with bare metal stents
were eligible for inclusion. Inclusion criteria comprised
randomised treatment allocation, comparison of
cobalt-chromium everolimus eluting stent versus bare metal
stent, and length of follow-up of at least a year. Exclusion
criteria were equivocal or non-random treatment allocation, lack
of outcome data up to one year, and duplicate reports. The two
reviewers resolved disagreements by consensus. All included
trials were reviewed and approved by ethics committees, and
all participants had given written informed consent. Two
investigators (MV and GF) systematically assessed the presence
of sources of bias by following the approach recommended by
the Cochrane Collaboration that identifies selection,
performance, attrition, detection, reporting bias, and other
sources of bias for each study, and classifies each of these as
low, unclear, or high by analysing the following domains:
random sequence generation, allocation concealment, blinding
of participants and of outcome assessment, incomplete outcome
data, selective outcome reporting, and “other issues.”14
Disagreements were resolved through consensus. A risk of bias
summary for each item for each included study was reported.
The meta-analysis was performed in agreement with the
PRISMA statement.15
Data extraction
We invited the principal investigators whose trials met the
inclusion criteria to participate in this collaborative analysis,
and they provided the following data for individual patients: a
set of core clinical variables consisting of demographics (age,
sex, body mass index (BMI)), cardiac risk factors (diabetes,
smoking, hypertension, and hypercholesterolaemia), clinical
manifestations (stable coronary artery disease, cardiac markers
negative unstable coronary artery disease, cardiac markers
positive unstable coronary artery disease without persistent ST
segment elevation myocardial infarction and persistent ST
segment myocardial infarction), angiographic factors (number
and type of diseased vessels, number of treated lesions, number
of implanted stents, overlapping stents implantation, total stent
length and average stent diameter), use of antithrombotic drugs
(actual duration of clopidogrel after treatment and use of
glycoprotein IIb/IIIa inhibitors during the procedure),
randomised treatment assignment, and outcomes in follow-up
(death, cardiac death, myocardial infarction, stent thrombosis,
repeat revascularisation, and last follow-up contact).
Two investigators (MV, GF) extracted data independently on
trial design, baseline characteristics, outcomes, and safety
events. After resolution of data queries, we recoded data from
each trial in a single dataset and checked data summaries from
individual trials against the associated publications for accuracy.
Endpoints
The primary outcome was cardiac mortality at the longest
available follow-up. We selected cardiac mortality and not all
cause mortality as primary outcome measure to minimise the
confounding effect of non-cardiac events on stent performance
in the context of a relatively old and unselected population of
patients followed-up through two years. Importantly, cardiac
mortality was homogenously classified across the five included
studies according to the ARC (Academic Research Consortium)
criteria.16
Secondary outcomes were all cause death, myocardial infarction
(fatal and non-fatal), stent thrombosis (definite and definite or
probable), target vessel revascularisation, a composite of cardiac
death and myocardial infarction, and a composite of all cause
death and myocardial infarction. The definition of stent
thrombosis was in alignment with the ARC criteria in four out
of five studies,11-13 17-19 whereas in the SPIRIT I trial20 stent
thrombosis was defined as a total coronary artery occlusion by
angiography at the stent site with abrupt onset of symptoms,
raised biochemical markers, and changes on electrocardiography
consistent with myocardial infarction. The definition of
myocardial infarction, which is summarised in table A in
appendix 1, differed among included trials largely because of
different criteria used to adjudicate peri-procedural
events.11-13 17-20 For all five studies, fatal and non-fatal
cardiovascular endpoints were confirmed on the basis of
documentation collected at each hospital and were centrally
adjudicated by clinical events committees, whosemembers were
unaware of patients’ assignments to treatment group.
Statistical analysis
We carried out an individual patient level data meta-analysis
using a “one stage” approach. Briefly, all data from individual
participants were combined in a single meta-analysis based on
a simple Cox proportional regression model stratified by trial,
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Bare metal stents
A bare metal stent is vascular stent without a coating (as used in drug eluting stents). It is a mesh-like tube of thin wire. The first stents
licensed for use in cardiac arteries were bare metal—often 316L stainless steel. More recent (“second generation”) stents use cobalt chromium
alloy. The major limitation of this coronary device is the so called risk for in stent restenosis, caused by proliferation of cells in the media
layer of the vessel wall leading to the growth of new tissue within the stent struts, called intimal hyperplasia, finally narrowing the vessel
lumen in a sizable proportion of patients. The growth of intimal hyperplasia peaks on average a few months after stent implantation and
remains thereafter stable. This stent requires the use of dual antiplatelet therapy for 30 days.
First generation drug eluting stents
They were primarily conceived to reduce in stent neointimal formation and therefore minimise the occurrence of restenosis, the major
drawback of percutaneous coronary interventions with bare metal stents. They consist of a metallic vascular stent coated with a permanent
polymer, which slowly releases a drug, such as sirolimus or paclitaxel, to block cell proliferation and thus limit intimal hyperplasia. The
permanent presence of these polymers has been associated with inflammatory responses and local toxicity in preclinical analysis. The
optimal duration of dual antiplatelet therapy after first generation drug eluting stents has never been conclusively determined, but it is likely
to be more than a year as this device has been associated with a fourfold to fivefold risk for very late (that is, after one year) stent thrombosis
compared with bare metal stents. On the other hand, rates of acute, subacute, and late stent thrombosis have been shown to be equal or
even lower than with bare metal stents.
Second generation drug eluting stents
They have been developed with thinner, more biocompatible, permanent, or bioabsorbable polymers, and new antiproliferative agents.
Whether technology based on erodible polymers—such as poly-l-lactic acid and poly-D,L-lactide, which control drug release after implantation
and vanish thereafter—is truly superior to technology engineered with biocompatible, thin, and durable material such as the fluorinated
polymer present in the cobalt-chromium everolimus eluting stent is still matter of debate. Second generation drug eluting stents have largely
been compared with first generation devices and some of them have been shown to be associated with a much lower risk of stent thrombosis,
both early and late. As with first generation drug eluting stents, the optimal duration of dual antiplatelet therapy after second generation drug
eluting stents has never been conclusively determined. No randomised study has so far reported safety issues in patients who discontinued
dual antiplatelet therapy after six or even three months after their implantation.
While first generation drug eluting stents have now been withdrawn from the market, clinical decision making regarding second generation
drug eluting stents versus bare metal stents currently depends on a complex interplay of several factors, including perceived risk for in stent
restenosis—if the perceived risk is low, a bare metal stent might be preferable, contraindications to long term dual antiplatelet therapy, and
costs.
containing random effects (frailty models) to assess the impact
of stent type—for instance, cobalt-chromium everolimus eluting
stent versus bare metal stent on outcome measures.21 We
calculated hazard ratios and 95% confidence interval for the
endpoints.
We also assessed the impact of stent type on outcomes by
multivariable Cox regression stratified by trial, with random
effects, entering into the model the following prespecified
clinically relevant covariates: clinical syndrome (that is, acute
coronary syndrome v stable syndrome), history of diabetes
mellitus, female sex, use of glycoprotein IIb/IIIa inhibitors, and
up to one year versus longer duration of dual antiplatelet therapy.
For each endpoint, we performed time to first event analysis.
When assessing each individual endpoint, we censored patients
who died from any cause beyond the time of death—that is,
they were not at risk anymore for the endpoint assessed after
they died.
We verified the proportional hazard assumptions by applying
a test for non-proportional hazards with the Schoenfeld residuals
and by visual estimation after plotting graphs of the scaled
Schoenfeld residuals against transformed time at follow-up after
index procedure and by adding time-by-covariate interactions
for each variable of the model, by introducing products between
the variables and a linear function of time.
As secondary analyses, we performed competing risk regression
models for endpoints other than death, considering all cause
mortality as the competing event. We calculated subhazard
ratios with 95% confidence interval (according to the method
of Fine and Gray,22 accounting for the clustered nature of the
data with trial as cluster) and have reported them in a
supplemental table. Subhazard ratios refer to the hazard that
generates failure events of interest while keeping participants
who experience competing events “at risk” so that they can be
adequately counted as not having any chance of failing.
In case of violation of the proportional hazard assumptions, we
calculated and report time dependent hazard ratios.
For target vessel revascularisation, and the composite of target
vessel revascularisation or myocardial infarction, for which
stent type effect presented a violation in proportional hazard
assumptions in bothmain and competing risk analyses, we report
a plot depicting Schoenfeld-like residuals against time with a
lowess smooth fitted through it from simple competing risk
regression model.
For outcomes not treated as competing events, we report
cumulative hazard curves of events, derived directly from the
simple Cox regression model built for hazard ratio calculation.
For endpoints assessed in competing risk analyses, we report
cumulative incidence curves of events, derived from the
corresponding simple regression model.
The numbers of patients needed to treat for an additional
beneficial or harmful outcome were calculated according to the
formula: NTT=1/{[Sc1(t)]−Sc0(t)}, where the Sc0(t) is the
survival probability at two years in the bare metal group and
[Sc1(t)] is the survival probability at two years in the
cobalt-chromium everolimus eluting stent group. Survival
probabilities were derived from simple Cox regression model
for mortality endpoints after estimation of baseline survival
functions and from simple competing risk regression model for
non-mortality endpoints.
We evaluated the presence of heterogeneity among studies with
the variance of random effects estimated by multivariable
stratified Cox regression models with random effects.
Additionally, we performed classic meta-analytic estimates of
heterogeneity with the Cochran Q χ2 test, where a P value ≤0.10
was considered as significant; with estimation of the variance
between studies with τ2 and by using I2 test to evaluate the
inconsistency. The I2 statistic is derived from the Q statistic
([Q−df/Q]*100) and describes the percentage of total variation
across studies attributable to heterogeneity: values of 25%, 50%,
and 75% correspond to low, moderate, and high heterogeneity.23
We could not statistically assess publication bias because we
had fewer than 10 studies. All analyses were conducted
according to the intention to treat principle. Categorical variables
are reported as counts and percentages and were compared by
χ2 or Fisher’s exact tests as appropriate. Continuous variables
are reported as means and SD or median and interquartile ranges
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whenever appropriate and were compared by t tests or Mann
Whitney U test as appropriate.
Subgroup analyses
We tested for interactions between assigned treatment and
baseline characteristics for the primary outcome measure of
cardiac death using stratified Cox models with random effects
that included treatment assignment, the baseline characteristic
of interest, and their interaction. We report coefficient
interactions with standard errors and P values for interaction.
The following covariates were tested for interaction: age ≥65,
sex, diabetes, use of glycoprotein IIb/IIIa inhibitors, duration
of dual antiplatelet therapy up to one year versus longer,
overlapping stent, clinical syndrome (acute coronary
syndrome/stable angina), treated culprit vessel, left descending
artery versus no left descending artery, and multi-vessel disease.
For descriptive purposes only, we have provided a plot of
treatment effects within each subgroup.
Sensitivity analyses
In a sensitivity analysis, we assessed the impact of treatment
assignment onmain outcomemeasure after censoring all patients
with cardiac fatalities temporarily associated (that is, occurring
within one week) with the occurrence of definite or probable
stent thrombosis.
In another sensitivity analysis we excluded one study (SPIRIT
I) with a sample size of fewer than 100 patients and assessed
the main outcome measure.
The level of significance for the summary treatment effect
estimate was two tailed P<0.05. We used R version 2.13.2 (the
R foundation for statistical computing), Stata 11.2 statistical
software (Statacorp LP, College Station, TX), and Review
Manager (RevMan) version 5.1 (2011, Nordic Cochrane Centre,
Cochrane Collaboration, Copenhagen) for statistical analyses.
Results
Of the 346 citations screened, we selected five randomised
controlled trials (fig 1⇓).11-13 17-20
The five participating trials provided data on 4896 patients
(tables 1-3⇓⇓⇓). The average age of the study population was
67, with about 57% and 33% patients aged 65 or 75 or older,
respectively. The XIMA population had the highest mean age
(83), followed by PRODIGY (69), BASKET PROVE (64),
SPIRIT I (63), and EXAMINATION (61). Table 1 shows the
baseline characteristics of the patients included in the trials.⇓
Overall, the proportion of women was slightly over 24% and
ranged from almost 40% inXIMA to 17% in EXAMINATION.
Diabetes mellitus was present in roughly 19% of overall
included patients. As a result of including two all comer
percutaneous coronary intervention studies11 13 and one all comer
ST segment myocardial infarction trial,12 44% of patients
(n=2129) received stenting in the setting of primary
percutaneous coronary intervention (table 2⇓) and more than
87% (n=4279) of patients underwent coronary treatment for an
unstable presentation, including 22% (n=1083) of patients with
non-ST segment myocardial infarction. The recommended
duration of treatment with clopidogrel after stenting differed
across studies, from one year for BASKET PROVE, at least
one year for EXAMINATION, at least three months in SPIRIT
I, and up to 6 or 24 months, according to the randomisation
scheme, in PRODIGY (table 3⇓. In the XIMA trial, the
recommended duration of clopidogrel was three months after
bare metal stents and 12 months after cobalt-chromium
everolimus eluting stents.
Notably, the comparator bare metal stent armwas homogenised
with the use of cobalt-chromium Vision stent in BASKET
PROVE, EXAMINATION, SPIRIT I, and XIMA17whereas the
choice of bare metal stent type was left at the discretion of the
treating physician in PRODIGY.
Median duration of follow-up was 720 days (interquartile range
719-720) in both groups. Complete two year follow-up data
were available for four studies,11 18-20 including 3933 (80.3%)
patients. Thirty nine (0.8%) patients (19 in the bare metal and
17 in the cobalt-chromium everolimus eluting stent group) were
lost to follow-up.
Bias assessment
Figure 2 shows the systematic bias analysis⇓. There was a low
risk of bias for most items for each study, except for the presence
of performance bias because of the lack of the double blind
design in each study. Further the potential for selection bias in
the SPIRIT I study was acknowledged.
Mortality endpoints
At two years, the risk of cardiac death was significantly reduced
in the cobalt-chromium everolimus eluting stent group at 2.7%
compared with 4.0% in the bare metal stent arm (hazard ratio
0.67, 95% confidence interval 0.49 to 0.91; P=0.01; fig 3⇓, table
4⇓. With multivariable regression, cardiac mortality remained
significantly lower in the cobalt-chromium everolimus eluting
stent group (0.69, 0.50 to 0.94; P=0.02; table 4).
Overall mortality was not significantly reduced in the
cobalt-chromium everolimus eluting stent group (4.9% v 5.9%;
unadjusted hazard ratio 0.83, 95% confidence interval 0.65 to
1.06; P=0.14; adjusted hazard ratio 0.84, 0.66 to 1.07; P=0.16)
(table 4⇓, fig A in appendix 2). There was evidence for small
non-significant heterogeneity for cardiac mortality (table A in
appendix 1).
Other fatal and/or non-fatal cardiovascular
endpoints
At two years, the risk of myocardial infarction was significantly
lower in the cobalt-chromium everolimus eluting stent group
(4.0% v 5.6% in the bare metal stent group; unadjusted hazard
ratio 0.71, 95% confidence interval 0.55 to 0.92; P=0.01;
adjusted hazard ratio 0.71, 0.55 to 0.93; P=0.01 (table 4⇓, fig
4⇓).
The risk of fatal myocardial infarction was significantly lower
in the cobalt-chromium everolimus eluting stent group
(unadjusted hazard ratio 0.11, 95% confidence interval 0.03 to
0.48, P=0.003; adjusted hazard ratio 0.11, 0.03 to 0.49, P=0.004;
table 4, fig 5⇓). No significant difference in the risk of non-fatal
myocardial infarction between groups was found (table 4, fig
B in appendix 2).⇓
Similarly, at two years the risk of definite stent thrombosis
(0.6% v 1.4%; adjusted hazard ratio 0.41, 95% confidence
interval 0.22 to 0.76; P=0.005; table 4⇓, fig 6⇓), definite or
probable stent thrombosis (1.3% v 2.6%; 0.48, 0.31 to 0.73;
P=0.001; table 4, fig 7⇓), and the need for re-intervention in the
previously treated vessel (4.3% v 10.2%; adjusted hazard ratio
0.29, 0.20 to 0.41; P<0.001; table 4, fig 8⇓) were all consistently
at least halved in the cobalt-chromium everolimus eluting stent
group.
Rates of the composite of target vessel revascularisation or
myocardial infarction, cardiac death or myocardial infarction,
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death, or myocardial infarction were significantly lower in the
cobalt-chromium everolimus eluting stent group (table 4⇓, figs
C-E in appendix 2).
Subhazard ratios calculated in competing risk analyses were
consistent with results of the main analysis for each endpoint
(table B in appendix 1).
For target vessel revascularization, and the composite of target
vessel revascularisation or myocardial infarction, we report a
plot depicting Schoenfeld-like residuals against time because
of the presence of time dependent hazard ratios (fig F in
appendix 2). Table C in appendix 1 shows the numbers needed
to treat for each endpoint.
Heterogeneity was null or minimal for the endpoints assessed.
We found a small non-significant heterogeneity for target vessel
revascularisation only (table A in appendix 1).
Subgroups and sensitivity analyses
As shown in figure 9⇓, the benefit of treatment with
cobalt-chromium everolimus eluting stents was consistent across
all analysed subgroups, including sex, age ≥65, presence of
diabetes, extension of coronary artery disease, need for
overlapping stents during the procedure, use of glycoprotein
IIb/IIIa inhibitors, treatment of left anterior descending artery,
and duration of dual antiplatelet therapy up to one year or
beyond.
We found an interaction for the type of coronary artery disease
at the time of intervention, indicating that patients presenting
with a stable disease phenotype might have a greater benefit
from treatment with cobalt-chromium everolimus eluting stents
with respect to cardiac death (fig 9⇓, table D in appendix 1).
At sensitivity analysis, the occurrence of definite or probable
stent thrombosis explained 47 (28.3%) fatal cardiac events.
After we censored these stent related events, the cardiac
mortality rate was lower at 2.8% in the bare metal stent group
and 2.1% in the cobalt-chromium everolimus eluting stent group,
which is not a significant difference (hazard ratio 0.76, 95%
confidence interval 0.53 to 1.10; P=0.15 by multivariable Cox
regression). After exclusion of the SPIRIT I study, the main
outcome measure remained unchanged.
Discussion
Our combined analysis of data from individual patients, most
of whom had acute coronary syndrome, from five randomised
open label or single blinded trials in which events were
independently and blinded adjudicated, shows that, compared
with bare metal stents, cobalt-chromium everolimus eluting
stent implantation is associated with a reduction in cardiac
mortality. This benefit came with a significant reduction in
myocardial infarction, fatal myocardial infarction, stent
thrombosis, and target vessel revascularisation.
Randomised clinical trials provide the reference standard for
comparing the effectiveness of treatments for a given clinical
condition. Yet the effectiveness of treatments on relatively rare
events, such as overall or cardiac mortality, might not be tested
adequately in a single study because of limited statistical power.
Combining individual patient data from multiple randomised
trials helps to overcome this limitation by increasing the number
of patients available for analysis, thus enhancing statistical
power.
In particular, individual patient data meta-analyses are
considered to be an ideal standard of systematic review as they
have been shown to produce more reliable results.24 Compared
with conventional meta-analyses that use aggregate data from
publications, the availability of individual patient data allowed
us to provide a more informative analysis of time dependent
data derived from the whole period of follow-upwith calculation
of hazard ratios. Moreover, an individual patient data
meta-analysis made possible an accurate definition of
prespecified subgroup of patients, allowing for consistency
assessment of study findings across predefined patient
subgroups. Finally, it allowed us to investigate the effect of
stent type on cardiac mortality after censoring specific fatal
events related to stent or procedure, as well as assessing the
robustness of our main study results by implementing both a
multivariable and competing risk assessment analyses.
Possible mechanisms
To get some insights into the possible mechanism leading to a
cardiac mortality benefit after cobalt-chromium everolimus
eluting stent implantation, at sensitivity analysis we censored
all cardiac fatalities temporarily associated (that is, occurring
within one week) with the occurrence of definite or probable
stent thrombosis. We chose a seven day time window to
maximise specificity even if it is known to underestimate the
actual burden of stent thrombosis in terms of cardiac fatalities.25
These events explained roughly a quarter of all cardiac fatalities
observed up to two years. After we censored these stent related
events, cardiac mortality was no longer different between the
two stent groups, suggesting a mechanistic interpretation of our
clinical observations. The lack of a significant difference in all
cause mortality, despite the difference in cardiac mortality, is
of interest. Crude non-cardiac mortality was 0.19%, 1.79%, and
4.02% in first, second, and last third of the age distribution,
respectively (P<0.001).
A potential diluting effect of benefit observed for
cobalt-chromium everolimus eluting stent on all cause mortality
could be ascribed to the higher non-cardiac mortality rate among
older patients.
Treatment effect was not altered by other characteristics of
patients, including sex, age, presence of diabetes, extension of
coronary artery disease, the need for overlapping stents, use of
glycoprotein IIb/IIIa inhibitors, treatment of left anterior
descending artery, or duration of clopidogrel therapy after
coronary stenting.
We found evidence of an interaction between treatment effect
and stent type for the acuity of coronary artery disease,
indicating that patients with stable coronary artery disease might
have greater benefit from treatment with cobalt-chromium
everolimus eluting stents in terms of cardiac mortality. This
could be chance a finding, however, because of the small sample
size of stable patients (n=610) and the multiple explored
subgroups (thereby inflating type I error). Further studies are
warranted to verify this hypothesis.
Comparison with other studies
After the widespread use of first generation drug eluting stents
in clinical practice, concern was raised that the reduction in
restenosis associated with these stents was achieved at the cost
of a potential increase in adverse clinical events, including death
and myocardial infarction.26-28 Long term treatment with dual
antiplatelets has been therefore advocated after implantation of
drug eluting stents,29 despite the absence of supporting evidence.
Considerable efforts have gone into the development of new
generation drug eluting stents that would retain the powerful
anti-restenosis properties of sirolimus and paclitaxel eluting
stents, yet provide improved deliverability and regain safety
profiles comparable with bare metal stents.30
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Most randomised trials, however, have compared second
generation drug eluting stents with their first generation
counterparts, and rarely with bare metal stents, thus restricting
a fully comparative understanding of their outcomes. No single
study comparing drug eluting with bare metal stents or different
types of drug eluting stents has ever been powered for mortality.
Hence, the lack of evidence coming from a single, albeit
relatively large, randomised controlled trial regarding the
proposed association between stent thrombosis and mortality
should be interpreted with the knowledge of the likelihood of
type II error.
Recently, a network meta-analysis of 49 randomised trials,
including 50 844 patients, suggested that cobalt-chromium
everolimus eluting stent was associated with a significant
reduction of definite stent thrombosis during two years of
follow-up compared with bare metal stent.31 That analysis,
however, included only two direct randomised trials comparing
cobalt-chromium everolimus eluting and bare metal stents,11 12
and follow-up data for over a year were available for only one11
of these two studies. Therefore, this network meta-analysis fell
short in dealing with the concern that very late stent thrombosis
(that is, beyond one year) might counterweigh early reduction
of thrombotic events. Notably this paradigm has also been
observed in pooled analyses of first generation drug eluting
versus bare metal stent.6 Different durations of dual antiplatelet
therapy in patients treated with the two types of stent or
differential use of antithrombotics at the time of intervention
are also possible confounding factors in this study, which were
not corrected for.31 Therefore, whether cobalt-chromium
everolimus eluting stents would provide sustained improved
safety over bare metal stents andmost importantly to what extent
this could translate into an improved survival rate remains so
far largely elusive.
Strengths and limitations
Our pooled analysis of 4896 patients, most of whom had acute
coronary syndrome, is the first to show a cardiac mortality
benefit associated with the use of a specific second generation
drug eluting stent—namely, cobalt-chromium everolimus
eluting—compared with a bare metal stent. This treatment effect
persisted after multivariable adjustment of confounders,
including duration of dual antiplatelet therapy after stenting and
use of glycoprotein IIb/IIIa inhibitors during the procedure.
Our observation that a durable polymer based drug eluting stent,
such as the cobalt-chromium everolimus eluting stent, offers
improved safety and efficacy profiles compared with non-active
polymer-free stents supports a major paradigm shift in our
understanding about coronary devices.
Firstly, stent safety and efficacy can no longer be disconnected
at least for some newer generation devices. Two studies have
so far randomised patients to first or second generation drug
eluting stents, including cobalt-chromium everolimus eluting
stent, to evaluate the optimal duration of treatment with
clopidogrel.32 33 These trials were largely underpowered to
conclusively assess the optimal duration of treatment after each
of the single stent to which patients have been randomised. Yet,
a distinct signal towards a possible increase of ischaemic events
after discontinuation of clopidogrel at six months has been
specifically observed after sirolimus or paclitaxel eluting stents
but not after cobalt-chromium everolimus eluting stents.
Additionally, because the durable polymer might not necessarily
harbour potential for thrombogenesis, it does not need to be
avoided in future. Recently, the rates of stent thrombosis were
reduced with fluorinated polymer coated stents compared with
equivalent bare metal stents in an experimental setting.34 Four
out of the five studies included in our pooled analysis compared
cobalt-chromium everolimus eluting stent with the uncoated
otherwise identical metallic stent, and they showed a reduction
in fatal and non-fatal adverse events consistent with the results
of our pooled analysis. It is therefore conceivable to attribute
the benefit for ischaemic events and cardiac mortality noted
here and elsewhere to the presence of the fluorinated
copolymer/drug coatings. Bare metal stent thrombogenicity has
long been recognised.35Copolymer coatings in cobalt-chromium
everolimus eluting stent are durable because of the hydrophobic
nature of fluorinated polymers, and they can act as a mechanical
barrier excluding metallic surface potential for thrombogenesis.
Moreover, fluorinated copolymer coatings are highly
electronegative and as such repel protein adsorption because of
their high electronegativity and elicit a cellular response
conducive to healing with minimal chronic inflammation.36
No single study has so far suggested a safety issue through over
three37 38 or even five years39 after cobalt-chromium everolimus
eluting stent implantation compared with first generation drug
eluting stents. Longer duration follow-up is required to confirm
the durability of the benefit observed here at a medium term
time point when cobalt-chromium everolimus eluting stents are
compared with bare metal stents.
Actual dual antiplatelet therapy status at follow-up was not11 or
was suboptimally17 recorded in two of the five included studies.
Hence, the role of concomitant antiplatelet therapy should be
further explored, bearing in mind that no single study has so far
reported a cardiac mortality benefit of clopidogrel therapy
beyond one month. No detailed information is available from
any of the included studies regarding patients who underwent
surgery throughout follow-up.
While an explanation for the observed reduction in cardiac
mortality in favour of cobalt-chromium everolimus eluting stent
can be only speculative at the present time, an interplay between
reduced device thrombegenicity as suggested by the lower stent
thrombosis and myocardial infarction rates coupled with
improved efficacy (that is, reduced need for target vessel
reintervention because of neointimal proliferation)might account
for the observed medium term cardiac survival benefit.
Conclusions and policy implications
This collaborative individual patient data meta-analysis of five
randomised controlled trials, including 4896 patients most with
acute coronary syndrome, shows a consistent reduction of
several fatal and non-fatal ischaemic endpoints in favour of
cobalt-chromium everolimus eluting stent compared with bare
metal stents, including cardiac mortality, stent thrombosis (both
definite and definite or probable), myocardial infarction, and
target vessel revascularisation throughout two year follow-up.
Our analysis challenges the current belief that bare metal stents
are safer than drug eluting stents. Stent safety and efficacy can
no longer be disconnected, at least for some newer generation
devices.
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What is already known on this topic
Coronary stents are widely used to treat patients with coronary artery disease, with drug eluting stents being more efficacious than bare
metal stents in preventing in stent restenosis and subsequent need for reintervention
As first generation drug eluting stents were associated with higher rates of stent thrombosis than bare metal stents, newer generation
drug eluting stents were developed to improve the safety and main the efficacy
Most randomised trials compared newer generation drug eluting stents with first generation stents, and rarely with bare metal stents,
restricting a fully comparative understanding of their outcomes
What this study adds
This individual patient data meta-analysis shows a consistent reduction of several fatal and non-fatal ischaemic endpoints in favour of
the newer generation everolimus eluting stent compared with bare metal stents, including significant reductions of cardiac mortality,
stent thrombosis, myocardial infarction, and target vessel revascularisation throughout two year follow-up
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Tables
Table 1| Clinical characteristics in 4896 patients in five trials in meta-analysis of effects of bare metal stent (BMS) or cobalt-chromium
everolimus eluting stents (DES) on fatal and non-fatal cardiovascular events. Figures are numbers (percentages) unless stated otherwise
XIMASPIRIT IBASKET PROVEEXAMINATIONPRODIGY
Overall
(n=4896)
DES
(n=399)
BMS
(n=401)
DES
(n=27)
BMS
(n=29)
DES
(n=774)
BMS
(n=765)
DES
(n=751)
BMS
(n=747)
DES
(n=501)
BMS
(n=502)
83.6 (3.2)83.4 (3.1)64.2
(9.6)
61.4
(9.3)
63.6 (10.7)64.1 (10.8)60.8 (12.2)61.6 (12.6)68.1 (11.3)68.9 (11.2)67 (13)Mean (SD) age (years)
155 (38.8)164 (40.9)8 (29.6)7 (24.1)187 (24.2)179 (23.4)117 (15.6)137 (18.3)107 (21.4)139 (27.7)1200
(24.5)
Female
102 (25.6)97 (24.2)3 (11.1)3 (10.3)119 (15.4)108 (14.1)137 (18.3)121 (16.2)113 (22.5)111 (22.1)914 (18.7)Diabetes
Smoking habit:
20 (5.0)16 (3.9)7 (25.9)9 (31.0)267 (34.5)261 (34.1)372 (49.6)386 (51.7)117 (23.4)126 (25.2)1581
(32.3)
Current smoker
165 (41.3)168 (41.9)2 (7.4)7 (24.1)229 (29.6)203 (26.5)172 (22.9)152 (20.3)124 (24.8)101 (20.2)1323
(27.0)
Former smoker
214 (53.6)217 (54.1)18 (66.7)13 (44.8)278 (35.9)301 (39.3)206 (27.5)209 (27.9)259 (51.8)272 (54.5)1987
(40.6)
Never
299 (75.1)311 (77.6)19 (70.4)15 (51.7)469 (60.6)485 (63.4)347 (46.3)378 (50.6)356 (71.1)376 (74.9)3055
(62.4)
Hypertension
230 (57.6)212 (52.9)20 (70.1)22 (75.9)498 (64.3)495 (64.7)354 (47.2)301 (40.3)294 (58.7)254 (50.6)2680
(54.7)
Hypercholesterolaemia
119 (29.8)86 (21.5)0082 (10.6)100 (13.1)33 (4.4)47 (6.3)143 (28.7)114 (22.8)724 (14.8)Previous MI
28 (7.0)17 (4.2)0020 (2.6)20 (2.6)3 (0.4)7 (0.9)61 (12.2)45 (8.9)201 (4.1)Previous CABG
MI=myocardial infarction; CABG=coronary artery bypass grafting.
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Table 2| Clinical presentation and treatment in 4896 patients in five trials in meta-analysis of effects of bare metal stent (BMS) or
cobalt-chromium everolimus eluting (DES) on fatal and non-fatal cardiovascular events. Figures are numbers (percentages) unless stated
otherwise
XIMASPIRIT IBASKET PROVEEXAMINATIONPRODIGY
Overall
(n=4896)
DES
(n=399)
BMS
(n=401)
DES
(n=27)
BMS
(n=29)
DES
(n=774)
BMS
(n=765)
DES
(n=751)
BMS
(n=747)
DES
(n=501)
BMS
(n=502)
128 (32.2)127 (31.7)27 (100)29 (100)41 (5.3)34 (4.4)00118 (23.6)111 (22.1)615 (15.6)Stable angina
pectoris
Acute coronary syndrome (ACS):
248 (62.3)237 (59.2)00619 (79.9)615 (80.4)00220 (43.9)211 (42.0)2150 (43.9)Non-ST
elevation ACS
22 (5.5)36 (9.0)00114 (14.7)116 (15.1)751 (100)747 (100)163 (32.5)180 (35.9)2129 (43.5)ST segment
elevation MI
Angiographic features:
130 (32.6)127 (31.7)20
(74.1)
23
(79.3)
455 (58.8)438 (57.2)634 (84.4)653 (87.4)145 (28.9)170 (33.9)2795 (57.1)Single vessel
disease
268 (67.2)270 (67.3)7 (25.9)6 (20.7)319 (41.2)327 (42.7)117 (15.6)94 (12.6)356 (71.1)332 (66.1)2096 (42.8)Multi-vessel
disease
246 (246)248 (61.8)13
(48.1)
13
(44.8)
417 (53.9)404 (52.8)326 (43.4)309 (41.4)260 (51.9)287 (57.2)2523 (51.5)LAD/LMCA
treated
99 (24.8)97 (24.2)6 (22.2)6 (20.7)202 (26.1)203 (26.5)102 (13.6)107 (14.3)186 (37.1)147 (29.3)1155 (23.6)CFX treated
132 (33.1)131 (32.7)8 (29.6)10
(34.5)
310 (40.0)325 (42.5)322 (42.9)329 (44.0)177 (35.3)190 (37.8)1934 (39.5)RCA treated
1.4 (0.6)1.4 (0.6)111.4 (0.8)1.5 (0.8)1.2 (0.4)1.1 (0.3)1.5 (0.9)1.5 (0.8)1.3 (0.69)No of treated
lesions
1.6 (1.1)1.6 (1.1)111.7 (1.1)1.7 (1.1)1.5 (0.8)1.5 (0.7)1.9 (1.2)1.8 (1.1)1.6 (1.0)No of stents
implanted
28.5 (22.9)29.1 (20.6)181831.1 (23.3)31.1 (22.5)27.9 (14.8)27.0 (13.2)39.6 (28.3)36.9 (30.1)30.9 (22.2)Total stent
length (mm)
2.9 (0.3)2.9 (0.3)333.5 (0.4)3.5 (0.3)3.2 (0.4)3.2 (0.4)2.9 (0.5)2.9 (0.5)3.2 (0.4)Stent size (mm)
75 (18.8)84 (20.9)00155 (20.0)150 (19.6)198 (26.4)206 (27.6)142 (28.3)139 (27.7)1149 (23.5)Overlapping
stents
32 (8.1)37 (9.4)2 (7.4)1 (3.4)176 (22.7)168 (21.9)400 (53.3)385 (51.5)219 (43.7)232 (46.2)1652 (33.8)Use of IIb/IIIa
inhibitors
002 (7.4)4 (13.8)00115 (15.3)98 (13.1)258 (51.6)230 (46.1)707 (14.4)No of patients
who continued
DAPT beyond
one year
DAPT=dual antiplatelet therapy; MI=myocardial infarction; RCA=right coronary artery; CFX=circumflex artery; LAD=left anterior descending artery; LMCA=left
main coronary artery.
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Table 3| Recommended duration (months) of dual antiplatelet therapy and follow-up treatment in three of five trials in meta-analysis of
effects of bare metal stent (BMS) or cobalt-chromium everolimus eluting (DES) on fatal and non-fatal cardiovascular events
XIMA (n=800)SPIRIT I (n=56)BASKET PROVE (n=1539)EXAMINATION (n=1498)PRODIGY (n=1003)
12≥312126 or 24*Experimental arm
3≥31212Up to 6 or 24*Control arm
15222Follow-up (years)
*1:1 randomisation.
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Table 4| Overall clinical outcomes in 4896 patients in five trials in meta-analysis by treatment assignment to bare metal stent (BMS) or
cobalt chromium-everolimus eluting stent (DES). Figures are numbers (percentage) of patients and hazard ratios (HR) from multivariable
Cox regression stratified by trial
Adjusted*UnadjustedEvent rate
Outcomes P valueHR (95% CI)P valueHR (95% CI)DES (n=2452)BMS (n=2444)
0.020.69 (0.50 to 0.94)0.010.67 (0.49 to 0.91)67 (2.7)99 (4.1)Cardiac death
0.160.84 (0.66 to 1.07)0.140.83 (0.65 to 1.06)121 (4.9)144 (5.9)Death from any cause
Myocardial infarction:
0.010.71 (0.55 to 0.93)0.010.71 (0.55 to 0.92)98 (4.0)136 (5.6)All
0.120.80 (0.61 to 1.05)0.120.81 (0.61 to 1.05)96 (3.9)118 (4.8)Non-fatal
0.0040.11 (0.03 to 0.49)0.0030.11 (0.03 to 0.48)2 (0.1)18 (0.8)Fatal
0.0050.41 (0.22 to 0.76)0.0060.42 (0.22 to 0.78)14 (0.6)33 (1.4)Definite stent thrombosis
0.0010.48 (0.31 to 0.73)0.0010.48 (0.31 to 0.74)31 (1.3)63 (2.6)Definite or probable stent
thrombosis
<0.0010.29 (0.20 to 0.41)<0.0010.29 (0.20 to 0.42)105 (4.3)250 (10.2)Target vessel
revascularisation
0.0010.27 (0.12 to 0.59)0.0010.27 (0.12 to 0.58)22 (0.9)44 (1.8)Target vessel myocardial
infarction
0.0080.76 (0.61 to 0.93)0.0060.75 (0.61 to 0.92)156 (6.4)207 (8.5)Cardiac death or
myocardial infarction
0.030.81 (0.68 to 0.98)0.0280.81 (0.68 to 0.98)206 (8.4)250 (10.2)Death or myocardial
infarction
*Adjusted for clinical syndrome (that is, acute coronary syndrome v stable syndrome), history of diabetes mellitus, female sex, use of glycoprotein IIb/IIIa inhibitors,
and up to 1 year v longer duration of dual antiplatelet therapy.
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Figures
Fig 1 Flow diagram of literature search for studies included in meta-analysis
Fig 2 Risk of bias summary reporting each risk of bias item for each included study
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Fig 3 Cumulative hazard for cardiac death and forest plot with point estimates and 95% confidence intervals for each
included study and pooled estimate from simple Cox regression model stratified by trial with random effects. Co-Cr
EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
Fig 4Cumulative incidence curve for myocardial infarction and forest plot with point estimates and 95% confidence intervals
for each included study and pooled estimate from simple Cox regression model stratified by trial with random effects. Co-Cr
EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
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Fig 5 Cumulative incidence curve for fatal myocardial infarction and forest plot with point estimates and 95% confidence
interval for each included study and pooled estimate from simple Cox regression model stratified by trial with random effects.
Co-Cr EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
Fig 6 Cumulative incidence curve for definite stent thrombosis and forest plot with point estimates and 95% confidence
interval for each included study and pooled estimate from simple Cox regression model stratified by trial with random effects.
Co-Cr EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6427 doi: 10.1136/bmj.g6427 (Published 4 November 2014) Page 15 of 17
RESEARCH
Fig 7 Cumulative incidence curve for definite or probable stent thrombosis and forest plot with point estimates and 95%
confidence interval for each included study and pooled estimate from simple Cox regression model stratified by trial with
random effects. Co-Cr EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
Fig 8Cumulative incidence curve for target vessel revascularisation and forest plot with point estimates and 95% confidence
interval for each included study and pooled estimate from simple Cox regression model stratified by trial with random effects.
Co-Cr EES=cobalt-chromium everolimus eluting; BMS=bare metal stent
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Fig 9 Subgroup analyses for treatment effect, with P value for interaction. IIb/IIIa=glycoprotein IIb/IIIa inhibitors
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